# OnCo record paper-ibis-i-tamoxifen-lancet-oncol-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-ibis-i-tamoxifen-lancet-oncol-2015" ;
  schema:name "IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years"@en ;
  schema:description "In women at increased risk, 5 years of tamoxifen reduced breast cancer by 29% over a median 16 years of follow-up, with the benefit continuing long after the pills stopped, but no reduction in breast cancer deaths."@en ;
  schema:url <https://onco.cc/key-papers/paper-ibis-i-tamoxifen-lancet-oncol-2015/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S1470-2045(14)71171-4>, <https://doi.org/10.1093/jnci/90.18.1371> ;
  schema:sameAs <https://doi.org/10.1016/S1470-2045(14)71171-4> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Cuzick J, Sestak I, Cawthorn S, et al." ;
  onco:related <https://onco.cc/ideas/idea-prev-low-dose-tamoxifen-uptake/>, <https://onco.cc/ideas/idea-prev-chemoprevention-master-protocol/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:sections <https://onco.cc/fronts/prevention/>, <https://onco.cc/fronts/hormonal/> ;
  onco:technologies <https://onco.cc/technologies/chemoprevention/>, <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/estrogen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/tamoxifen/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-prevention-adoption/>, <https://onco.cc/bottlenecks/b-hereditary-risk/>, <https://onco.cc/bottlenecks/b-toxicity-qol/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .